Monitor WW's future earnings reports for Med+ membership growth trends and any update on partnership-driven revenue. While this improves patient affordability, it does not directly boost WW's top line unless it translates into higher enrollment or retention.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $13.74entry
- T+1 · 8mo ago +2.33%α +1.58% · $14.06
- T+5 · 7mo ago −17.76%α −21.70% · $11.30
- T+20 · 7mo ago −29.99%α −39.41% · $9.62
- T+60 · 5mo ago +16.38%α +3.99% · $15.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
WW International announced an expanded collaboration with Novo Nordisk to offer eligible Med+ members discounted subscription pricing for Wegovy, saving up to $1,200 annually. This enhances access to GLP-1 treatment and reinforces WW's integrated weight health model, though no financial impact on revenue or profitability was quantified.
Key Facts
- WW International and Novo Nordisk expanded their collaboration to offer subscription pricing for Wegovy to eligible Med+ members.
- Members can save up to $1,200 per year, or up to $100/month on pens and $50/month on pills, via pre-paid 3, 6, or 12-month plans.
- The offer applies to all Wegovy pen doses and 9 mg/25 mg pill doses; existing limited-time offers also remain available.
- WW is a NovoCare® Recognized Care Provider and emphasizes combining medication with lifestyle support for better outcomes.
- No financial terms, revenue impact, or membership uptake figures were disclosed.
Financial Impact
No direct financial impact disclosed; potential indirect benefit from increased Med+ membership demand.
Risk Factors
- No material financial benefit if increased access does not drive higher Med+ adoption.
- Dependence on Novo Nordisk's supply and pricing policies, which are outside WW's control.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265364 |
Track record
20 reports on WW
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +9.16% at T+20 after the Apr 3, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $9.46 Now $9.46 +0.00% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $10.84 Now $9.46 −12.73% settles Dec 15
- Nov 10, 20266d ago Insider Cluster Bullish 4/10 Entry $13.05 Now $9.46 −27.51% settles Dec 10
- Nov 5, 202611d ago 8-K Mixed 6/10 Entry $12.84 Now $9.46 −26.32% settles Dec 4
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $14.27 to $13.05 Now $9.46 +33.71% ▲ +8.55% +7.28% vs SPY
- Sep 9, 20269w ago 8-K Neutral 4/10 Entry $14.94 to $15.08 Now $9.46 −36.68% ▲ +0.94% −1.01% vs SPY
- Aug 20, 202612w ago Insider Buy Bullish 5/10 Entry $15.71 to $16.39 Now $9.46 −39.78% ▲ +4.33% +4.85% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $13.34 to $15.71 Now $9.46 −29.09% ▲ +17.77% +14.14% vs SPY
- Jun 16, 202621w ago Press Release Bullish 5/10 Entry $19.05 to $14.87 Now $9.46 −50.34% ▼ −21.94% −23.26% vs SPY
- Jun 4, 202623w ago DEFA14A Neutral 5/10 Entry $17.27 to $16.31 Now $9.46 −45.21% ▼ −5.53% −4.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers